Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Warts 2Neurofibromatosis 1 2Breast Neoplasms 2Stomatitis 1Retinoblastoma 1Retinal Neoplasms 1Prostatic Neoplasms 1Port-Wine Stain 1Pancreatic Neoplasms 1Osteoma, Osteoid 1Nevus of Ota 1Neurofibromatoses 1Neoplasms 1Mucositis 1Lymphedema 1Keratosis, Actinic 1Hemangioma, Capillary 1Cholangiocarcinoma 1Bile Duct Neoplasms 1Atrophy 1

Interventions

Gemcitabine 406Oxaliplatin 131Fluorouracil 125130-nm albumin-bound paclitaxel 108Capecitabine 100Albumin-Bound Paclitaxel 90Leucovorin 88Irinotecan 87Radiotherapy 76Radiosurgery 64Taxes 63Cisplatin 56Erlotinib Hydrochloride 44Drug Therapy 42folfirinox 40Magnetic Resonance Spectroscopy 39pembrolizumab 35Blood Specimen Collection 33S 1 (combination) 31Pancreaticoduodenectomy 31Docetaxel 31Nivolumab 30Bevacizumab 30Biopsy 26Surgical Procedures, Operative 25Cyclophosphamide 25irinotecan sucrosofate 24Specimen Handling 24Radiation 22Standard of Care 21

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Pancreatic Neoplasms × Lasers × Clear all
NCT02702986 2022-04-21

Safety and Feasibility of imILT Locally Advanced Pancreatic Cancer (LAPC)

Universita di Verona

Phase 1 Completed
10 enrolled
Gastrointestinal

Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡